{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:40:27Z","timestamp":1787582427874,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanxi Medical Association Clinical Research Project","award":["YSXH-QL2023XY001"],"award-info":[{"award-number":["YSXH-QL2023XY001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15642-x","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:05:43Z","timestamp":1770087943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic factors and nomogram development for adult diffuse large B-cell lymphoma: a single-center retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"3","key":"15642_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"1","key":"15642_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74\u201387.","journal-title":"Pathology"},{"issue":"1","key":"15642_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the united States, 1992\u20132001. Blood. 2006;107(1):265\u201376.","journal-title":"Blood"},{"issue":"9","key":"15642_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"12","key":"15642_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de l\u2019adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"issue":"2","key":"15642_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/crst.crst_94_22","volume":"5","author":"P Pandey","year":"2022","unstructured":"Pandey P, Gogia A. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. Cancer Res Stat Treat. 2022;5(2):350.","journal-title":"Cancer Res Stat Treat"},{"key":"15642_CR7","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","DOI":"10.1182\/blood-2017-03-769620"},{"issue":"27","key":"15642_CR8","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-Cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol"},{"issue":"14","key":"15642_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A Predictive Model","year":"1993","unstructured":"A Predictive Model. For aggressive Non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med"},{"issue":"14","key":"15642_CR10","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20\u2009+\u2009B-Cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373\u201380.","journal-title":"J Clin Oncol"},{"issue":"23","key":"15642_CR11","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041\u20138.","journal-title":"Blood"},{"issue":"4","key":"15642_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood.V54.4.928.928","volume":"54","author":"AM Ferraris","year":"1979","unstructured":"Ferraris AM, Giuntini P, Gaetani GF. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979;54(4):928\u201332.","journal-title":"Blood"},{"issue":"1","key":"15642_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/hon.2188","volume":"34","author":"C Yoo","year":"2015","unstructured":"Yoo C, Yoon DH, Kim S, Huh J, Park C-S, Park C-J, et al. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Hematol Oncol. 2015;34(1):22\u20137.","journal-title":"Hematol Oncol"},{"key":"15642_CR14","doi-asserted-by":"crossref","unstructured":"Cottereau A-S, Nioche C, Dirand A-S, Clerc J, Morschhauser F, Casasnovas O, et al. 18\u2009F-FDG PET dissemination features in diffuse large B-Cell lymphoma are predictive of outcome. J Nucl Med. 2019;61(1):40\u20135.","DOI":"10.2967\/jnumed.119.229450"},{"issue":"7","key":"15642_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15642_CR16","doi-asserted-by":"crossref","unstructured":"Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2011;118(17):4173\u201383.","DOI":"10.1002\/cncr.27396"},{"issue":"20","key":"15642_CR17","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood. 2013;121(20):4021\u201331.","journal-title":"Blood"},{"issue":"11","key":"15642_CR18","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","volume":"29","author":"LH Sehn","year":"2011","unstructured":"Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15642_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364\u201370.","journal-title":"J Clin Oncol"},{"issue":"20","key":"15642_CR20","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"15642_CR21","doi-asserted-by":"crossref","unstructured":"Jardin F, Tilly H. Diffuse Large B-Cell Lymphoma. In: Lymphoma. Humana Press; 2013. p. 177\u2013202.","DOI":"10.1007\/978-1-62703-408-1_11"},{"issue":"27","key":"15642_CR22","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201367.","journal-title":"J Clin Oncol"},{"key":"15642_CR23","doi-asserted-by":"crossref","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201356.","DOI":"10.1097\/00000421-198212000-00014"},{"issue":"28","key":"15642_CR24","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452\u20139.","journal-title":"J Clin Oncol"},{"issue":"26","key":"15642_CR25","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-Cell lymphoma cell of origin determined by digital gene expression in Formalin-Fixed Paraffin-Embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848\u201356.","journal-title":"J Clin Oncol"},{"key":"15642_CR26","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v116\u201325.","journal-title":"Ann Oncol"},{"issue":"12","key":"15642_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"15642_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837.","journal-title":"Biometrics"},{"issue":"31","key":"15642_CR29","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N, Voelker H-U, Cuccuini W, Hirchaud E, et al. The germinal Center\/Activated B-Cell subclassification has a prognostic impact for response to salvage therapy in Relapsed\/Refractory diffuse large B-Cell lymphoma: A Bio-CORAL study. J Clin Oncol. 2011;29(31):4079\u201387.","journal-title":"J Clin Oncol"},{"key":"15642_CR30","doi-asserted-by":"crossref","unstructured":"Pileri S. Faculty opinions recommendation of molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Faculty Opinions \u2013 Post-Publication peer review of the biomedical literature. H1 Connect; 2018.","DOI":"10.3410\/f.733128725.793554330"},{"issue":"5","key":"15642_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"4","key":"15642_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. 2022;386(4):351\u201363.","journal-title":"N Engl J Med"},{"issue":"5","key":"15642_CR33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F, et al. Liposomal doxorubicin supercharge-containing front\u2010line treatment in patients with advanced\u2010stage diffuse large B\u2010cell lymphoma or classical hodgkin lymphoma: preliminary results of a single\u2010centre phase II study. Br J Haematol. 2022;198(5):847\u201360.","journal-title":"Br J Haematol"},{"issue":"28","key":"15642_CR34","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical Double-Hit score is a strong predictor of outcome in patients with diffuse large B-Cell lymphoma treated with rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15642_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2017","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2017;25(1):27\u201336.","journal-title":"Cell Death Differ"},{"issue":"24","key":"15642_CR36","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","volume":"122","author":"G Ott","year":"2013","unstructured":"Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884\u201391.","journal-title":"Blood"},{"issue":"2","key":"15642_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","volume":"31","author":"A Rosenthal","year":"2017","unstructured":"Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31(2):37\u201342.","journal-title":"Blood Rev"},{"key":"15642_CR38","doi-asserted-by":"crossref","unstructured":"Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273\u20139.","DOI":"10.1182\/blood-2009-03-212191"},{"issue":"1","key":"15642_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hon.3098","volume":"41","author":"SH Desai","year":"2022","unstructured":"Desai SH, Mwangi R, Smith AN, Maurer MJ, Farooq U, King RL, et al. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma. Hematol Oncol. 2022;41(1):39\u201349.","journal-title":"Hematol Oncol"},{"issue":"6","key":"15642_CR40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1600-0609.2006.00644.x","volume":"76","author":"J Campbell","year":"2006","unstructured":"Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76(6):473\u201380.","journal-title":"Eur J Haematol"},{"key":"15642_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"6","key":"15642_CR42","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00277-021-04537-5","volume":"100","author":"M Picardi","year":"2021","unstructured":"Picardi M, Cavaliere C, Della Pepa R, Nicolai E, Soricelli A, Giordano C, et al. PET\/MRI for staging patients with hodgkin lymphoma: equivalent results with PET\/CT in a prospective trial. Ann Hematol. 2021;100(6):1525\u201335.","journal-title":"Ann Hematol"},{"issue":"12","key":"15642_CR43","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/1097-0142(19830615)51:12<2220::AID-CNCR2820511212>3.0.CO;2-A","volume":"51","author":"H Hagberg","year":"1983","unstructured":"Hagberg H, Killander A, Simonsson B. Serum\u03b22-microglobulin in malignant lymphoma. Cancer. 1983;51(12):2220\u20135.","journal-title":"Cancer"},{"issue":"11","key":"15642_CR44","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas R-O, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"26","key":"15642_CR45","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: A risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150\u20136.","journal-title":"J Clin Oncol"},{"key":"15642_CR46","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600\u20139.","DOI":"10.1182\/blood.2020006578"},{"issue":"6769","key":"15642_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1186\/s12885-026-16810-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15642-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15642-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15642-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:01:59Z","timestamp":1787580119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15642-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15642"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15642-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Ethics approval number is corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-026-16810-9","URL":"https:\/\/doi.org\/10.1186\/s12885-026-16810-9","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee of Cancer Hospital Affiliated to Shanxi Medical University (approval number: KY2025214). Written informed consent was obtained from all participants or their legally authorized representatives prior to enrollment in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"335"}}